The content on this page is intended to healthcare professionals and equivalents.
Fusion of “Diagnosis” with “Treatment”
to deliver required drugs with appropriate dose to target site effectively
With improvement in living environment and the level of medical care, and populations aging worldwide in recent years, increased cases of cancer and cognitive impairment have become social serious issues.
Infection diseases are also expanding due to increasing movement of people globally and multiple types of drug-resistant bacteria.
It has been being revealed that many of those diseases have complex mechanisms to make pathology and progression different in relevant patients and are thus difficult to be effectively treated via standard of medical care.
As a total healthcare company, Fujifilm tries to address these issues with a unique approach that combines various technologies such as chemistry, biology, imaging, and artificial intelligence (AI) and thereby fusion of “diagnosis” with “treatment.”
Fujifilm also aims to realize medical care that truly improves patient quality of life (QOL) by establishing mechanisms that “to deliver required drugs with appropriate dose to target site effectively” through target-based drug discovery and development of radiopharmaceuticals and drug delivery system (DDS) as well.
This will simultaneously provide various effects including improved burden of medical costs resulting from the improvement of drug safety and the reduction of unnecessary drug treatment.
Change medical care and the society as well by changing the ideal pharmaceuticals—the vision of Fujifilm’s pharmaceutical business.
Conventional Standard Medical Treatment
Pharmaceutical Business of Fujifilm Group
(2) Administration of an Antibacterial Agent Specific to a Bacterial Strain Identified with In Vitro Diagnosis
In recent years, frequent uses of broad-spectrum antibacterial agents have have caused a worldwide problem due to the development of bacteria and viruses with antimicrobial resistance (AMR) worldwide. Fujifilm seeks to realize target-based therapy to ensure treatment with antibacterial agents specific to bacterial strains in infected patients that are precisely identified with in vitro diagnostic systems of the Fujifilm Group. Fujifilm aims to improve effectiveness of treatment, and restrict the spread of AMR resulting from attack on non-target bacterial strains.
(3) Assessment of Effectiveness of Radiopharmaceuticals in Advance for the Treatment of Cancers (Theranostics)
Provides small molecular drugs, radiopharmaceuticals, contrast agents, and diagnostic adjuvants.
Provides contrast agents (generic drugs).
Provides clinical reagents (in vitro diagnostics).